Due to improved molecular examinations today, EC is now classified according to the ProMisE-algorithm, containing MMR-deficiency, POLE mutation, p53 wildtype and p53 aberrancy (Kommoss et al. 2018; Kandoth et al. 2013). The gene discussed is TP53; the disease is mismatch repair cancer syndrome 1.